S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
Recent Reports Are A Wake-Up Call For Investors (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
Recent Reports Are A Wake-Up Call For Investors (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
An Unusual Way to Invest in Gold (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
Recent Reports Are A Wake-Up Call For Investors (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
Recent Reports Are A Wake-Up Call For Investors (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
An Unusual Way to Invest in Gold (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
Recent Reports Are A Wake-Up Call For Investors (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
Recent Reports Are A Wake-Up Call For Investors (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
An Unusual Way to Invest in Gold (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
Recent Reports Are A Wake-Up Call For Investors (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
Recent Reports Are A Wake-Up Call For Investors (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
An Unusual Way to Invest in Gold (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary

Clene Stock Price, News & Analysis (NASDAQ:CLNN)

$0.41
+0.01 (+2.52%)
(As of 12/7/2023 ET)
Compare
Today's Range
$0.40
$0.42
50-Day Range
$0.38
$0.54
52-Week Range
$0.36
$1.99
Volume
315,499 shs
Average Volume
580,275 shs
Market Capitalization
$52.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.80

Clene MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,818.3% Upside
$7.80 Price Target
Short Interest
Healthy
0.45% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$102,501 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.28) to ($0.34) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

379th out of 960 stocks

Pharmaceutical Preparations Industry

126th out of 381 stocks


CLNN stock logo

About Clene Stock (NASDAQ:CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

CLNN Stock Price History

CLNN Stock News Headlines

Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?
A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.
Insider Spends US$103k Buying More Shares In Clene
Benchmark Co. Keeps Their Buy Rating on Clene (CLNN)
The Battery Metal Nobody Told You About
According to McKinsey and Company, the battery storage market is growing rapidly, especially with the transition to clean, renewable energy. Lithium-ion batteries still grab most of the headlines. But analysts now call safe and long-lasting batteries made with vanadium "the future of battery tech."
Clene Inc. (CLNN) Interactive Stock Chart - Yahoo Finance
Clene Inc. Is 'One to Watch'
See More Headlines
Receive CLNN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/07/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/11/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CLNN
Fax
N/A
Employees
75
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.80
High Stock Price Target
$13.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+1,818.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-29,920,000.00
Net Margins
-5,624.65%
Pretax Margin
-5,624.65%

Debt

Sales & Book Value

Annual Sales
$718,000.00
Book Value
$0.04 per share

Miscellaneous

Free Float
94,257,000
Market Cap
$52.21 million
Optionable
Not Optionable
Beta
0.53
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Robert Etherington MBA (Age 56)
    CEO, President & Director
    Comp: $590.98k
  • Mr. Morgan R. Brown CPA (Age 55)
    M.B.A., Chief Financial Officer
    Comp: $374.05k
  • Mr. Mark G. Mortenson ESQ. (Age 65)
    Chief Science Officer
    Comp: $482.98k
  • Mr. Jerry Miraglia J.D.
    General Counsel & Corporate Secretary
  • Mr. Michael T. Hotchkin
    Chief Development Officer
  • Ms. Mary Anne Mcneil
    Head of Human Resources
  • Dr. Benjamin M. Greenberg M.D.
    M.H.S., Head of Medical














CLNN Stock Analysis - Frequently Asked Questions

Should I buy or sell Clene stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Clene in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CLNN shares.
View CLNN analyst ratings
or view top-rated stocks.

What is Clene's stock price target for 2024?

6 analysts have issued 1 year price targets for Clene's stock. Their CLNN share price targets range from $4.00 to $13.00. On average, they predict the company's stock price to reach $7.80 in the next twelve months. This suggests a possible upside of 1,818.3% from the stock's current price.
View analysts price targets for CLNN
or view top-rated stocks among Wall Street analysts.

How have CLNN shares performed in 2023?

Clene's stock was trading at $1.00 at the beginning of 2023. Since then, CLNN stock has decreased by 59.3% and is now trading at $0.4066.
View the best growth stocks for 2023 here
.

When is Clene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 11th 2024.
View our CLNN earnings forecast
.

How were Clene's earnings last quarter?

Clene Inc. (NASDAQ:CLNN) announced its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.08. The company had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.14 million. Clene had a negative trailing twelve-month return on equity of 322.31% and a negative net margin of 5,624.65%.

Who are Clene's major shareholders?

Clene's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include AIGH Capital Management LLC (4.52%), Vivo Capital LLC (2.06%), Worth Venture Partners LLC (1.09%), Silverarc Capital Management LLC (0.39%), AE Wealth Management LLC (0.13%) and Kepos Capital LP (0.10%). Insiders that own company stock include Alison Mosca, David J Matlin, David J Matlin, General Resonance Llc, John Henry Stevens, Jonathon Gay, Robert Dee Etherington and Robert Glanzman.
View institutional ownership trends
.

How do I buy shares of Clene?

Shares of CLNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CLNN) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -